Lenvima (lenvatinib) — CareFirst (Caremark)
Endometrial carcinoma
Initial criteria
- Used in combination with pembrolizumab (Keytruda)
- AND Member has advanced or recurrent disease that is mismatch repair proficient (pMMR)
- OR Member has advanced disease that is mismatch repair deficient (dMMR) and has progressed following prior platinum-based chemotherapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months